These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 529054)

  • 41. Bezafibrate treatment in primary hypercholesterolaemia. Possibility of intermittent treatment.
    Fringes B; Riede UN; von Deimling O
    Atherosclerosis; 1982 Sep; 44(3):391-2. PubMed ID: 7150401
    [No Abstract]   [Full Text] [Related]  

  • 42. Assessment of gastric antisecretory effects of phenoxyisobutyrate derivatives in the rat and the mouse.
    Eason CT; Pattison A; Howells DD; Spencer AJ; Bonner FW
    Scand J Gastroenterol; 1988 Nov; 23(9):1063-71. PubMed ID: 3247588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days.
    Desager JP; Horsmans Y; Vandenplas C; Harvengt C
    Atherosclerosis; 1996 Jul; 124 Suppl():S65-73. PubMed ID: 8831918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on eicosanoid concentrations in rat liver.
    Wilson MW; Leung LK; Hong JT; Glauert HP
    Adv Exp Med Biol; 1997; 400A():439-45. PubMed ID: 9547588
    [No Abstract]   [Full Text] [Related]  

  • 45. Peroxisome proliferator-induced alterations in the expression and modification of rat hepatocyte plasma membrane proteins.
    Bartles JR; Khuon S; Lin XH; Zhang LQ; Reddy JK; Rao MS; Isoye ST; Nehme CL; Fayos BE
    Cancer Res; 1990 Feb; 50(3):669-76. PubMed ID: 2404574
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peroxisomal enzyme activities in brain and liver of pups of lactating mothers treated with ciprofibrate.
    Singh I; Lazo O
    Neurosci Lett; 1992 Apr; 138(2):283-6. PubMed ID: 1608540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
    Charmoillaux M; Goudonnet H; Mercenne F; Mounié J; Truchot RC
    Cell Mol Biol; 1991; 37(8):765-71. PubMed ID: 1807786
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blood levels, tissue distribution and the duration of action in rats of ciprofibrate, a new hypolipidemic agent.
    Edelson J; Benziger DP; Arnold A; Beyler AL
    Atherosclerosis; 1979 Jul; 33(3):351-7. PubMed ID: 486226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Research regarding the action of a derivative of the clofibric acid series on lipid metabolism].
    Filip M; Păduraru I; Hriscu A; Neacşu R; Dănilă G; Filip F
    Rev Med Chir Soc Med Nat Iasi; 1987; 91(2):341-5. PubMed ID: 3685700
    [No Abstract]   [Full Text] [Related]  

  • 50. Inhibition of liver glutathione S-transferase activity in rats by hypolipidemic drugs related or unrelated to clofibrate.
    Foliot A; Touchard D; Mallet L
    Biochem Pharmacol; 1986 May; 35(10):1685-90. PubMed ID: 3707598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator.
    Rao MS; Lalwani ND; Watanabe TK; Reddy JK
    Cancer Res; 1984 Mar; 44(3):1072-6. PubMed ID: 6692393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of beclobric acid and clofibric acid on peroxisomal beta-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes.
    Blaauboer BJ; van Holsteijn CW; Bleumink R; Mennes WC; van Pelt FN; Yap SH; van Pelt JF; van Iersel AA; Timmerman A; Schmid BP
    Biochem Pharmacol; 1990 Aug; 40(3):521-8. PubMed ID: 2383284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.
    Chianale J; Vollrath V; Wielandt AM; Amigo L; Rigotti A; Nervi F; Gonzalez S; Andrade L; Pizarro M; Accatino L
    Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):781-6. PubMed ID: 8615769
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of peroxisome proliferation in hepatocytes transplanted into the anterior chamber of the eye. A model system for the evaluation of xenobiotic-induced effects.
    Rao MS; Thorgeirsson S; Reddy MK; Lalwani ND; Evarts RE; Usman MI; Singh B; Reddy JK
    Am J Pathol; 1986 Sep; 124(3):519-27. PubMed ID: 3532814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute muscular syndrome after bezafibrate.
    Bock KD
    Klin Wochenschr; 1981 Dec; 59(23):1321. PubMed ID: 7311399
    [No Abstract]   [Full Text] [Related]  

  • 57. The antilipemic effectiveness of aluminium clofibrate on hyperlipidemic patients with or without diabetes mellitus.
    Lam HC; Li SH; Wang JT; Tang KT; Ho LT
    Zhonghua Yi Xue Za Zhi (Taipei); 1987 Nov; 40(5):463-70. PubMed ID: 3332236
    [No Abstract]   [Full Text] [Related]  

  • 58. [Rhabdomyolysis under treatment by ciprofibrate in the nephrotic syndrome].
    Baglin A; Lasserre N; Prinseau J; Lebas M
    Therapie; 1987; 42(2):247-8. PubMed ID: 3617003
    [No Abstract]   [Full Text] [Related]  

  • 59. Species differences in the hepatic response to a potent peroxisome proliferator.
    Makowska JM; Bonner FW; Goldfarb PS; Gibson GG
    Biochem Soc Trans; 1989 Dec; 17(6):1072-3. PubMed ID: 2628085
    [No Abstract]   [Full Text] [Related]  

  • 60. [Hypolipemic effect of amino acid derivatives of clofibric acid].
    Wójcicki J; Samochowiec L; Gawrońska-Szklarz B; Kwapiszewski W; Borkowski L
    Acta Pol Pharm; 1985; 42(3):305-8. PubMed ID: 4096253
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.